title: A comparison of florfenicol and tulathromycine for the treatment of undifferentiated fever in feedlot calves.
abstract: The purpose of this study was to compare the relative cost-effectiveness of florfenicol with that of tulathromycin for treatment of undifferentiated fever (UF) in feedlot calves at ultra-high risk of developing UF that receive metaphylactic tulathromycin on arrival at the feedlot. Calves that received therapeutic florfenicol had lower overall mortality (P=.045) and bovine respiratory disease mortality (P=.050) compared with calves that received therapeutic tulathromycin, but no significant differences were detected in feedlot performance, carcass characteristics, or other animal health variables. There was a net advantage of Can$41.19/treated animal in the florfenicol group versus the tulathromycin group. This study demonstrates that it is more cost-effective to use florfenicol than tulathromycin for the initial treatment of UF in feedlot calves at ultra-high risk of developing UF that receive on-arrival metaphylactic tulathromycin.
authors.affiliation: Feedlot Health Management Services Ltd., Okotoks, Alberta, Canada.
authors.forename: Tye
authors.initials: T
authors.lastname: Perrett
authors.forename: Sameeh M
authors.initials: SM
authors.lastname: Abutarbush
authors.forename: Brian K
authors.initials: BK
authors.lastname: Wildman
authors.forename: Maria T
authors.initials: MT
authors.lastname: Fuchs
authors.forename: Oliver C
authors.initials: OC
authors.lastname: Schunicht
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Pollock
authors.forename: R Kent
authors.initials: RK
authors.lastname: Fenton
authors.forename: G Kee
authors.initials: GK
authors.lastname: Jim
authors.forename: P Timothy
authors.initials: PT
authors.lastname: Guichon
authors.forename: Calvin W
authors.initials: CW
authors.lastname: Booker
authors.forename: Janice
authors.initials: J
authors.lastname: Berg
authors.forename: Joe
authors.initials: J
authors.lastname: Roder
authors.forename: Mark
authors.initials: M
authors.lastname: Spire
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D048090:Bovine Respiratory Disease Complex / Q000188:drug therapy* / Q000401:mortality; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000401:mortality; D003362:Cost-Benefit Analysis; D004187:Disaccharides / Q000191:economics / Q000627:therapeutic use*; D005334:Fever / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D006571:Heterocyclic Compounds / Q000191:economics / Q000627:therapeutic use*; D013839:Thiamphenicol / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D018942:Macrolides
chemical_list: D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D013839:Thiamphenicol; C035534:florfenicol; C485204:tulathromycin; D018942:Macrolides